Payment overview · 2025
General Payments
$100.30
4 reported records · 2 companies
Healthcare provider profile · identity verified
Anthony J Curci, DO
Allopathic & Osteopathic Physicians|Family Medicine · WILMINGTON, DE · NPI 1801893144
Verified facts
What the public records show
CMS Open Payments records show Anthony J Curci, DO received $100.30 in general payments during 2025 across 4 reported records.
GlaxoSmithKline, LLC. accounted for 53.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.45 | 53.3% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $46.85 | 46.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $100.30 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $46.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 92 |
| Alprazolam | Alprazolam | 283 | 51 |
| Metformin Hcl | Metformin Hcl | 245 | 75 |
| Lisinopril | Lisinopril | 227 | 71 |
| Omeprazole | Omeprazole | 225 | 71 |
| Losartan Potassium | Losartan Potassium | 195 | 61 |
| Gabapentin | Gabapentin | 182 | 61 |
| Simvastatin | Simvastatin | 175 | 56 |
| Glimepiride | Glimepiride | 143 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 47 |
| Methylprednisolone | Methylprednisolone | 113 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 27 |
| Montelukast Sodium | Montelukast Sodium | 90 | 33 |
| Trazodone Hcl | Trazodone Hcl | 90 | 20 |
| Famotidine | Famotidine | 89 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 87 | 31 |
| Furosemide | Furosemide | 84 | 32 |
| Celecoxib | Celecoxib | 81 | 26 |
| Allopurinol | Allopurinol | 80 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 28 |
| Mirtazapine | Mirtazapine | 74 | 23 |
| Atenolol | Atenolol | 69 | 21 |
| Januvia | Sitagliptin Phosphate | 68 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 23 |
| Tramadol Hcl | Tramadol Hcl | 65 | 12 |
| Lorazepam | Lorazepam | 64 | 14 |
| Jardiance | Empagliflozin | 61 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 16 |
| Chlorthalidone | Chlorthalidone | 55 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 14 |
| Ezetimibe | Ezetimibe | 52 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 49 | suppressed |
| Nifedipine Er | Nifedipine | 48 | 13 |
| Alendronate Sodium | Alendronate Sodium | 47 | 16 |
| Carvedilol | Carvedilol | 47 | 15 |
| Potassium Chloride | Potassium Chloride | 46 | 16 |
| Valsartan | Valsartan | 46 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 43 | 14 |
| Verapamil Er | Verapamil Hcl | 41 | 13 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Terazosin Hcl | Terazosin Hcl | 38 | 12 |
| Azithromycin | Azithromycin | 37 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Eliquis | Apixaban | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 15 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Fluconazole | Fluconazole | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 14 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100.30 · 4 records | GlaxoSmithKline, LLC. | SHINGRIX, TZIELD | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error